ENB001 nanoparticle formulation for sustained systemic delivery of BQ788. Pre-Clinical POC across multiple cancer types. Established safety profile of BQ788 derisks the path to clinical development. Lead product to launch in limited initial oncology indications.
Second generation NCE deuterated ETBR antagonist. Pre-clinical POC for reversing anti-PD1 resistance. To be developed for expansion into broad oncology indications.
CNS targeted formulations to treat glioblastoma, CNS lymphoma and melanoma that has spread to the CNS.